Recombinant Lactaptin Induces Immunogenic Cell Death and Creates an Antitumor Vaccination Effect in Vivo with Enhancement by an IDO Inhibitor

Recombinant Lactaptin Induces Immunogenic Cell Death and Creates an Antitumor Vaccination Effect in Vivo with Enhancement by an IDO Inhibitor

Natural compounds of various origins are intensively investigated for their antitumor activity. Potential benefits of antitumor therapy can be achieved when cytotoxic agents kill cancer cells and these dying cancer cells drive adoptive immunity to the tumor. This strategy was successfully demonstrat...

Full description

Bibliographic Details
Main Authors:	Olga Troitskaya, Mikhail Varlamov, Anna Nushtaeva, Vladimir Richter, Olga Koval
Format:	Article
Language:	English
Published:	MDPI AG 2020-06-01
Series:	Molecules
Subjects:	milk peptides recombinant lactaptin immunogenic cell death antitumor vaccination indoleamine 2,3-dioxygenase inhibitor
Online Access:	https://www.mdpi.com/1420-3049/25/12/2804

Similar Items

Comparative analysis of lactaptin activity when produced in bacterial or eukaryotic expression systems
by: O. A. Koval, et al.
Published: (2017-12-01)

Nucleic Acids Delivery Into the Cells Using Pro-Apoptotic Protein Lactaptin
by: Olga Chinak, et al.
Published: (2019-09-01)

Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?
by: Cemil Bilir, M.D., et al.
Published: (2017-07-01)

Single-nucleotide polymorphisms and activities of indoleamine 2,3-dioxygenase isoforms, IDO1 and IDO2, in tuberculosis patients
by: Tingming Cao, et al.
Published: (2022-01-01)

TRYPTOPHAN AND INDOLEAMINE-2,3-DIOXYGENASE (IDO) IN PATHOGENESIS OF IMMUNOSUPPRESSIVE CLINICAL CONDITIONS
by: V. A. Kozlov, et al.
Published: (2017-07-01)

IDO1 Protein Is Expressed in Diagnostic Biopsies from Both Follicular and Transformed Follicular Patients
by: Marie Beck Hairing Enemark, et al.
Published: (2023-04-01)

Increased Indoleamine 2,3-Dioxygenase 1 (IDO-1) Activity and Inflammatory Responses during Chikungunya Virus Infection
by: Thiara Manuele Alves de Souza, et al.
Published: (2022-04-01)

Tumor Microenvironment‐Activated Nanocomposite for Self‐Amplifying Chemodynamic/Starvation Therapy Enhanced IDO‐Blockade Tumor Immunotherapy
by: Yulong Bian, et al.
Published: (2023-12-01)

Synthesis, Docking and Biological Evaluation of a Novel Class of Imidazothiazoles as IDO1 Inhibitors
by: Marta Serafini, et al.
Published: (2019-05-01)

IDO Expression in Cancer: Different Compartment, Different Functionality?
by: Annabel Meireson, et al.
Published: (2020-09-01)

Deletion of indoleamine 2,3 dioxygenase (Ido)1 but not Ido2 exacerbates disease symptoms of MOG35-55-induced experimental autoimmune encephalomyelitis
by: Lisa A. Wetzel, et al.
Published: (2020-08-01)

On the nonredundant roles of TDO2 and IDO1
by: Paolo ePuccetti
Published: (2014-10-01)

IDO and CD40 May Be Key Molecules for Immunomodulatory Capacity of the Primed Tonsil-Derived Mesenchymal Stem Cells
by: Hyun-Joo Lee, et al.
Published: (2021-05-01)

CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis
by: Fangxuan Li, et al.
Published: (2019-12-01)

Immunological Effects of Cold Atmospheric Plasma-Treated Cells in Comparison with Those of Cells Treated with Lactaptin-Based Anticancer Drugs
by: Olga Troitskaya, et al.
Published: (2022-09-01)

What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past
by: Yu Yao, et al.
Published: (2021-02-01)

Discovery of Icotinib-1,2,3-Triazole Derivatives as IDO1 Inhibitors
by: Long-fei Mao, et al.
Published: (2020-09-01)

IDO/kynurenine pathway in cancer: possible therapeutic approaches
by: Eslam E. Abd El-Fattah
Published: (2022-08-01)

Progesterone decreased indoleamine 2,3-dioxygenase 1(IDO1) expression in early pregnancy chorionic villi and decidua
by: Minyan Yang, et al.
Published: (2021-04-01)

Interactions of IDO and the Kynurenine Pathway with Cell Transduction Systems and Metabolism at the Inflammation–Cancer Interface
by: Trevor W. Stone, et al.
Published: (2023-05-01)

Immunomodulatory Factors in Primary Endometrial Cell Cultures Isolated from Cancer and Noncancerous Human Tissue–Focus on RAGE and IDO1
by: Joanna Tkaczuk-Włach, et al.
Published: (2021-04-01)

Antiviral activity of interferon-γ involved in impaired immune function in infectious diseases
by: Sucher Robert, et al.
Published: (2013-12-01)

Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO-1) Inhibitors Based on Ortho-Naphthaquinone-Containing Natural Product
by: Hongchuan Zhao, et al.
Published: (2019-03-01)

Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation
by: Xi Xu, et al.
Published: (2019-01-01)

Indoleamine 2,3-Dioxygenase (IDO) Activity: A Perspective Biomarker for Laboratory Determination in Tumor Immunotherapy
by: Pengbo Yang, et al.
Published: (2023-07-01)

Discovery of Novel 1,2,3-triazole Derivatives as IDO1 Inhibitors
by: Xixi Hou, et al.
Published: (2022-10-01)

The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1
by: Eleonora Panfili, et al.
Published: (2023-04-01)

Design, Synthesis and Biological Evaluation of Phenyl Urea Derivatives as IDO1 Inhibitors
by: Chuan Zhou, et al.
Published: (2020-03-01)

First-in-Class, Thiosemicarbazide-Based, Dual Inhibitors of Human DNA Topoisomerase IIα and Indoleamine-2,3-Dioxygenase 1 (IDO-1) with Strong Anticancer Properties
by: Barbara Kaproń, et al.
Published: (2022-11-01)

IDO1 Modulates the Sensitivity of Epithelial Ovarian Cancer Cells to Cisplatin through ROS/p53-Dependent Apoptosis
by: Houmei Wang, et al.
Published: (2022-10-01)

Synthesis and Molecular Modeling Studies of N′-Hydroxyindazolecarboximidamides as Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors
by: Dong-Ho Lee, et al.
Published: (2017-11-01)

Tryptophan-degrading enzymes in tumoral immune resistance
by: Nicolas van Baren, et al.
Published: (2016-11-01)

Indoleamine 2,3-Dioxygenase Is Involved in Interferon Gamma’s Anti-BKPyV Activity in Renal Cells
by: Tony Fiore, et al.
Published: (2020-08-01)

Low Levels of Serum Tryptophan Underlie Skeletal Muscle Atrophy
by: Soranobu Ninomiya, et al.
Published: (2020-04-01)

Indoleamine 2,3- Dioxygenase: A Novel Immunotherapeutic Target for Osteosarcoma
by: Asim Farooq, et al.
Published: (2022-09-01)

Serum neopterin concentrations and tryptophan degradation pattern in patients with late stage larynx carcinoma
by: Engin Ayse Basak, et al.
Published: (2017-08-01)

Neopterin suppresses the activity of tryptophan-degrading enzyme indoleamine 2,3-dioxygenase in human peripheral blood mononuclear cells
by: Schroecksnadel Sebastian, et al.
Published: (2013-12-01)

Wine and Grape Juice Modulate Interferon-y-induced Neopterin Production and Tryptophan Degradation in Human PBMC
by: Neurauter Gabriele, et al.
Published: (2004-02-01)

Interplay Between Mitophagy and Apoptosis Defines a Cell Fate Upon Co-treatment of Breast Cancer Cells With a Recombinant Fragment of Human κ-Casein and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand
by: Fabian Wohlfromm, et al.
Published: (2021-01-01)

Efficient tumor synergistic chemoimmunotherapy by self-augmented ROS-responsive immunomodulatory polymeric nanodrug
by: Jinxiao Song, et al.
Published: (2023-03-01)